FCCC LOGO Faculty Publications
Local Control and Toxicity of External Beam Reirradiation With a Pulsed Low-dose-rate Technique
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4) :959-964
PMID: 29485075    PMCID: PMC7537409    URL: https://www.ncbi.nlm.nih.gov/pubmed/29485075
Back to previous list
PURPOSE: To evaluate the efficacy and toxicity of external beam reirradiation using a pulsed low-dose-rate (PLDR) technique. METHODS AND MATERIALS: We evaluated patients treated with PLDR reirradiation from 2009 to 2016 at a single institution. Toxicity was graded using the Common Terminology Criteria for Adverse Events, version 4.0, and local control was assessed using the Response Evaluation Criteria In Solid Tumors, version 1.1. On univariate analysis (UVA), the chi(2) and Fisher exact tests were used to assess the toxicity outcomes. Competing risk analysis using cumulative incidence function estimates were used to assess local progression. RESULTS: A total of 39 patients were treated to 41 disease sites with PLDR reirradiation. These patients had a median follow-up time of 8.8 months (range 0.5-64.7). The targets were the thorax, abdomen, and pelvis, including 36 symptomatic sites. The median interval from the first radiation course and reirradiation was 26.2 months; the median dose of the first and second course of radiation was 50.4 Gy and 50 Gy, respectively. Five patients (13%) received concurrent systemic therapy. Of the 39 patients, 9 (23%) developed grade >/=2 acute toxicity, most commonly radiation dermatitis (5 of 9). None developed grade >/=4 acute or subacute toxicity. The only grade >/=2 late toxicity was late skin toxicity in 1 patient. On UVA, toxicity was not significantly associated with the dose of the first course of radiation or reirradiation, the interval to reirradiation, or the reirradiation site. Of the 41 disease sites treated with PLDR reirradiation, 32 had pre- and post-PLDR scans to evaluate for local control. The local progression rate was 16.5% at 6 months and 23.8% at 12 months and was not associated with the dose of reirradiation, the reirradiation site, or concurrent systemic therapy on UVA. Of the 36 symptomatic disease sites, 25 sites (69%) achieved a symptomatic response after PLDR, including 6 (17%) with complete symptomatic relief. CONCLUSION: Reirradiation with PLDR is effective and well-tolerated. The risk of late toxicity and the durability of local control were limited by the relatively short follow-up duration in the present cohort.
1879-355x Lee, Charles T Dong, Yanqun Li, Tianyu Freedman, Samuel Anaokar, Jordan Galloway, Thomas J Hallman, Mark A Weiss, Stephanie E Hayes, Shelly B Price, Robert A Ma, C M Charlie Meyer, Joshua E Journal Article United States Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):959-964. doi: 10.1016/j.ijrobp.2017.12.012. Epub 2017 Dec 23.